



# Immunomic Therapeutics' Dr. Larry Weiner to Present at ACAAI Meeting 11/10/13

*Immunomic Therapeutics' Medical Monitor, Dr. Lawrence Weiner, to Present at the 2013 ACAAI Annual Scientific Meeting November 10th in Baltimore, MD.*

HERSHEY, PA, UNITED STATES, October 22, 2013 /EINPresswire.com/ -- FOR IMMEDIATE RELEASE Immunomic Therapeutics, Inc., ("ITI") a privately-held biotechnology company with laboratories in Rockville, MD, announced that it has been accepted to present at the 2013 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology, taking place November 7-11, 2013, at the Baltimore Convention Center. ITI's Medical Monitor, Lawrence Weiner, will present the results of ITI's Phase IA Study of JRC-LAMP-Vax™, a DNA Immunotherapy Vaccine to Treat Japanese Red Cedar Allergy.

At the event, ITI will present findings of the Phase I trial of JRC-LAMP-vax vaccine, conducted at ITI's clinical site in Honolulu, Hawaii, and completed in May 2013. The Company is pleased to report that JRC-LAMP-vax™ met all of its primary safety end points. Within the three subject subgroups, (24 total patients) there were no reports of any Severe Adverse Events. In addition to monitoring vaccine safety, subjects were also evaluated for allergic skin test status as a secondary endpoint for immunological responses. The allergic marker results indicate a favorable trend in resolving the allergy. Specifically, a number of the subjects, both skin test positive and skin test negative at the start of the trial, were found to be skin test negative at the end of the study: 10 of 12 converted from positive to negative for whole JRC extract and all subjects were negative for the specific cedar allergen Cry J2. Dr. Weiner will also be presenting preliminary data from the Phase IB study which recruited most of the Phase I patients for additional skin test monitoring.

The ACAAI 70th Annual Scientific Meeting (November 7-11, 2013 in Baltimore, MD), entitled, "New Frontiers in Allergy and Immunology: From Bench to Clinic," will feature a variety of educational sessions for physicians and allied health professionals. This event is an opportunity for ITI to meet with allergists and immunologists, potential future collaborators, clinical investigators and future prescribers of LAMP-vax vaccines. At the event, ITI's Medical Monitor, Dr. Lawrence Weiner, will be presenting in more detail regarding LAMP technology and mechanism, the objectives, study design and findings of the Phase IA clinical study, as well as future clinical development plans. Dr. Weiner is scheduled to speak during Session C - Aerobiology; Allergy Testing/Clinical Laboratory Immunology; Immunotherapy/Immunizations on Sunday, November 10th at 2:30 PM at the Baltimore Convention Center. (Rooms 307-309)

ITI's CEO, Bill Hearl, commented, "We are excited about this opportunity for ITI to showcase its technology and clinical findings, in order to educate with and build awareness of LAMP technology and LAMP-allergy immunotherapies in the allergy community."

#### About ACAAI

The American College of Allergy, Asthma and Immunology, established in 1942, is a professional association of more than 5,700 Allergists/Immunologists and allied health professionals. See [www.acaai.org](http://www.acaai.org) for more information.

#### About Lawrence Weiner, M.D.

Dr. Lawrence Weiner, M.D. is a seasoned expert in allergy and immunology, and for 34 years headed Carolina Allergy & Asthma Consultants. Dr. Weiner received a Doctor of Medicine from Syracuse Medical School, and served as Chief Resident of Pediatrics Syracuse. He went on to become a fellow in the Division of Immunology and Allergy at Univ. of Texas (Galveston).

#### About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented LAMP Technology. Our LAMP-vax platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy, cancer and infectious diseases. For more information about ITI and LAMP Technology please visit [www.immunomix.com](http://www.immunomix.com).

#### Bill Hearl

Immunomic Therapeutics, Inc.

717-327-1919

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/173145087>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.